References
Grönberg H, Adolfsson J, Aly M et al (2015) Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. doi:10.1016/S1470-2045(15)00361-7
Welch HG, Gorski DH, Albertsen PC (2015) Trends in metastatic breast and prostate cancer-lessons in cancer dynamics. N Engl J Med 373:1685–1687. doi:10.1056/NEJMp1510443
Arnsrud Godtman R, Holmberg E, Lilja H et al (2014) Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol 68:354–360. doi:10.1016/j.eururo.2014.12.006
Nordström T, Aly M, Clements MS et al (2013) Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003–2011. Eur Urol 63:419–425. doi:10.1016/j.eururo.2012.10.001
Drazer MW, Huo D, Eggener SE (2015) National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 33:2416–2423. doi:10.1200/JCO.2015.61.6532
Rider JR, Sandin F, Andrén O et al (2013) Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 63:88–96. doi:10.1016/j.eururo.2012.08.001
Grönberg H, Adolfsson J, Aly M et al (2016) Abstract 86: the STHLM3 model improves prostate cancer testing in men 50–69 years—further health economic and clinic evaluation. Eur Urol Suppl 15:1–1167. doi:10.1016/S1569-9056(16)60088-X
Authors’ contributions
ME was involved in project development, data analysis, and manuscript writing. HG developed the project, collected data, and wrote the manuscript. TN collected data and wrote the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
HG has five prostate cancer diagnostic-related patents pending, has patent applications licensed to Thermo Fisher Scientific, and might receive royalties from sales related to these patents. ME is named on four of these five patent applications.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Nordström, T., Eklund, M. & Grönberg, H. Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study—Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. World J Urol 35, 895–896 (2017). https://doi.org/10.1007/s00345-016-1907-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00345-016-1907-2